https://www.selleckchem.com/pr....oducts/gusacitinib.h
Current evidence on antipsychotic treatment and risk of psychiatric hospitalization in first-episode schizophrenia (FES) is largely based on the findings from randomized clinical trials (RCTs). However, the generalization of the findings to real-world patients is limited due to inherent caveats of the RCT. We aimed to investigate the treatment discontinuation and risk of psychiatric hospitalization using a nationwide population database. The Health Insurance Review Agency database in South Korea was obtained, and the observation per
Like
Comment
Share
